BMS-986340 (Not yet branded)
Other Medications
Description
BMS-986340 is an immunotherapy agent being developed for microsatellite stable (MSS) colorectal cancer, a patient population that typically responds poorly to standard checkpoint inhibitors. The compound is designed to work in combination with nivolumab and chemotherapy regimens to enhance immune response in treatment-refractory colorectal cancer patients. Based on clinical trial data, it appears to function as an immune system modulator that may help overcome resistance mechanisms in MSS tumors.
Mechanism of Action
BMS-986340 works by targeting specific immune regulatory pathways to enhance T-cell activation and tumor recognition in microsatellite stable colorectal cancers. The drug is designed to complement checkpoint inhibition by addressing additional immune suppressive mechanisms that prevent effective anti-tumor responses in MSS tumors.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | IV |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.